Achieve Life Sciences, Inc. QUIT
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.80% | 103.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.65% | 75.78% | |||
| Operating Income | -11.65% | -75.78% | |||
| Income Before Tax | 83.80% | -635.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 83.80% | -635.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 83.80% | -635.34% | |||
| EBIT | -11.65% | -75.78% | |||
| EBITDA | -11.67% | -76.20% | |||
| EPS Basic | 85.64% | -319.74% | |||
| Normalized Basic EPS | 85.67% | -307.76% | |||
| EPS Diluted | 85.64% | -319.74% | |||
| Normalized Diluted EPS | 85.67% | -307.76% | |||
| Average Basic Shares Outstanding | 12.80% | 75.17% | |||
| Average Diluted Shares Outstanding | 12.80% | 75.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||